Tag:
GlaxoSmithKline
Latest Headlines
Latest Headlines
GSK gambles on biotech partners after dubious M&A deal
GlaxoSmithKline ($GSK) has shown in a series of M&A and investment moves that the London-based drug giant prefers to bet on known commodities--existing biotech partners. Bloomberg analyzed GSK's strategy and speculates that the company could pick one of its collaborators as a future buyout target.
Pharma giants join forces on $285M antibiotics collaboration
GlaxoSmithKline, Sanofi, AstraZeneca, J&J as well as Basilea will join an R&D consortium including Europe's Innovative Medicines Initiative to fund the effort, setting up an information hub that will share data among investigators laboring on new antibiotics.
GSK tweaks Human Genome bid to include poison pill antidote
The two companies are at loggerheads over a deal. HGS says that Glaxo simply waited until its share price hit rock bottom before offering a bargain basement price for the maker of Benlysta. GSK says it's being more than fair.
GSK inks deal to co-promote Auxilium testosterone gel
Amid a surge in sales of testosterone products, GlaxoSmithKline has signed on to market a testosterone-replacement gel from Auxilium Pharmaceuticals.
Reuters: Drugmakers crafting emergency plan for Greece
Drugmakers are putting together a plan for how to keep medications flowing to Greece if the economy collapses and payments become uncertain.
HGS puts 'poison pill' in its arsenal against GSK
Human Genome Sciences has added a poison pill to its portfolio as it tries to fend off the hostile takeover by its longtime partner GlaxoSmithKline.
HGS faces skeptics as it boasts of a crowded bargaining table
Human Genome Sciences has prescribed a poison pill for GlaxoSmithKline's hostile takeover bid.
GSK lands one-two punch in melanoma trial
Data from the small mid-stage trial provide early evidence that GSK's two-drug combo could have an edge over Roche's approved melanoma drug Zelboraf.
Cancer drug experts brace for ASCO abstract dump tonight
ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
GSK snags proteomics platform tech in $98M Cellzome buyout
GSK has opted to buy out the company for $98 million, snagging full rights to a pair of early-stage inflammation programs and a proteomics technology.
